Compare · RMD vs SSKN
RMD vs SSKN
Side-by-side comparison of ResMed Inc. (RMD) and Strata Skin Sciences Inc. (SSKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and SSKN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.13B, about 697.1x SSKN ($49.0M).
- RMD has hit the wire 9 times in the past 4 weeks while SSKN has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 0 for SSKN).
- Company
- ResMed Inc.
- Strata Skin Sciences Inc.
- Price
- $236.53+1.73%
- $0.19-38.08%
- Market cap
- $34.13B
- $49.0M
- 1M return
- -
- +0.00%
- 1Y return
- -
- -88.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2005
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Strata Skin Sciences Inc.
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of psoriasis, vitiligo, atopic dermatitis, eczema, and other skin disorders. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Latest RMD
- 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
- Rothschild & Co Redburn initiated coverage on ResMed with a new price target
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
Latest SSKN
- STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer
- New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA's Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
- SEC Form 10-K filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form 15-12G filed by Strata Skin Sciences Inc.
- SEC Form POS AM filed by Strata Skin Sciences Inc.
- SEC Form POS AM filed by Strata Skin Sciences Inc.
- SEC Form S-8 POS filed by Strata Skin Sciences Inc.